Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9879027 | 0.98 | GSK3B (0.58) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL9879032 | 0.97 | GSK3B (0.56) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL4059184 | 0.86 | GSK3B (0.56) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL490430 | 0.85 | GSK3B (0.54) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL3471710 | 0.83 | GSK3B (0.56) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL14624168 | 0.81 | GSK3B (0.63) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL14624174 | 0.81 | GSK3B (0.54) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL6781684 | 0.80 | DAO (0.52) | DAOGAAKDM4EPOLBCASP3 | |
| SCHEMBL15686222 | 0.79 | GSK3B (0.59) | GSK3BCES2CES1DAONPSR1 | |
| SCHEMBL7902938 | 0.79 | HPGD (0.38) | GSK3BNPSR1GAAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724127-B | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-02 | — | — | US | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| EP-4053124-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-09-07 | — | — | EP | disclosed |
| CN-114829357-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083060-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | 中国科学院上海药物研究所 | 2021-05-06 | — | — | WO | disclosed |
| CN-112724127-A | Five-membered heterocyclic oxocarboxylic acid compound and medical application thereof | 中国科学院上海药物研究所 | 2021-04-30 | — | — | CN | disclosed |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| CN-1026234-C | Thiazolidinedione derivatives for lowering blood glucose | PFIZER (US) | 1994-10-19 | — | — | CN | disclosed |
| EP-0332332-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| WO-1992016565-A1 | WRINKLED ABSORBENT PARTICLES OF HIGH EFFECTIVE SURFACE AREA HAVING FAST ABSORPTION RATE | THE DOW CHEMICAL COMPANY (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5130379-A | Anticholesterol agents and antidiabetic agents | PFIZER INC. (US) | 1992-07-14 | — | — | US | disclosed |
| US-5036079-A | Anticholesterol | PFIZER INC. (US) | 1991-07-30 | — | — | US | disclosed |
| WO-1991003474-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONE DERIVATIVES | PFIZER INC. (US) | 1991-03-21 | — | — | WO | disclosed |
| CN-1036572-A | Thiazolidinedione derivatives for lowering blood glucose | PFIZER (US) | 1989-10-25 | — | — | CN | disclosed |
| EP-0332332-A1 | Hypoglycemic thiazolidinedione derivatives | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | GSK3B 904/4885CES2 2429/4885CES1 55/4885 |
| US-20230032101-A1 | FIVE-MEMBERED HETEROCYCLIC OXOCARBOXYLIC ACID COMPOUND AND MEDICAL USE THEREOF | STING1, CGAS, IRF3 | GSK3B 3353/4885CES2 3721/4885CES1 1859/4885 |
| US-20150148334-A1 | HETEROARYLS AND USES THEREOF | RICTOR, AKT2, MTOR | GSK3B 74/4885CES2 1393/4885CES1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.